FEASIBILITY OF MOLECULAR DIAGNOSIS OF α-THALASSEMIA IN THE EVALUATION OF MICROCYTOSIS

PIERA SIVERA, ANTONELLA ROETTO, UMBERTO MAZZA, CLARA CAMASCHELLA

*Dipartimento di Scienze Biomediche e Oncologia Umana; °Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliera S. Luigi, Orbassano, Italy

ABSTRACT

Microcytosis is a common hematological finding, usually related to iron deficiency or β-thalassemia. When both of these conditions are excluded, α-thalassemia must be considered in the differential diagnosis. No simple biochemical test is able to diagnose the α-thalassemia trait. Using PCR amplification of the breakpoint in deletional forms, and amplification of the α2 gene and restriction enzyme digestion in non-deletional forms, we identified the α-thalassemia carrier status in 42 out of 51 (82%) patients with microcytosis or slight microcytic anemia, unrelated to iron deficiency or β-thalassemia. Our results underline the usefulness of molecular tests in clinical practice.

Key words: α-thalassemia, microcytosis, PCR

Microcytic anemia is a common hematological abnormality, usually resulting from iron deficiency or β-thalassemia.

Although α-thalassemia (for review see refs. #1 and #2) is frequent in Italy, detailed data on its incidence throughout the country are not available. No simple biochemical test is able to diagnose α-thalassemia carriers, who have one or two α genes inactivated. The reduced α-chain availability decreases both hemoglobin A and A2, leaving their respective proportions unchanged at hemoglobin electrophoresis. Globin chain synthesis studies are both expensive and time-consuming, and cannot provide the correct diagnosis in a significant proportion of cases, due to overlapping α/non-α ratios between normal and α-thalassemia carriers.1,2

Knowledge about the molecular basis of α-thalassemia allows for the specific analysis of the molecular defects. A series of tests are available in order to amplify the breakpoints in deletional forms,2–6 and the ability of selectively amplifying both α2 and α1 genes provides the opportunity of studying non-deletional forms.7 Investigating five molecular defects, we diagnosed α-thalassemia in 42/51 (82%) consecutive patients referred for microcytosis or mild microcytic anemia, unrelated both to β-thalassemia and iron deficiency.

Patients and Methods

Fifty-one subjects (23 males and 28 females) were included in the study. Nineteen were referred for microcytosis or mild microcytic anemia, unrelated to iron deficiency or β-thalassemia. When both of these conditions were excluded, α-thalassemia must be considered in the differential diagnosis. No simple biochemical test is able to diagnose the α-thalassemia trait. Using PCR amplification of the breakpoint in deletional forms, and amplification of the α2 gene and restriction enzyme digestion in non-deletional forms, we identified the α-thalassemia carrier status in 42 out of 51 (82%) patients with microcytosis or slight microcytic anemia, unrelated to iron deficiency or β-thalassemia. Our results underline the usefulness of molecular tests in clinical practice.

Key words: α-thalassemia, microcytosis, PCR

Results

PCR assays using primers C2-C10 produced 2.1 Kb fragments in normal cases and 1.9 Kb fragments in the presence of αα7 deletion. Similarly, specific primers identified the breakpoint of ---Med and αα20.5.6 To test for the T→C substitution at the initiation codon and for the pentanucleotide deletion in intron 1 of the α2 gene, a PCR product obtained using primers C3 and C10 was digested with Nco I or Hph I enzymes, respectively.

Table 1 shows the genotypes observed in the series examined. As expected, αα7 was the most common form, with nineteen heterozygotes and five homozygotes. Next we found the αα2 T→C substitution. Both --Med and the pentanucleotide deletion were rare, and αα20.5 was never observed in this series, but was detected only in cases of Hb H disease (not shown). Mean MCV was 76 fL (range

Correspondence: Clara Camaschella, Dipartimento di Scienze Biomediche e Oncologia Umana, Azienda Ospedaliera S. Luigi, Orbassano 10043 Torino, Italy. Tel. international +39.11.9026610. Fax international +39.11.9038636. E-mail: camaschella@ope.net

Acknowledgements: the authors wish to thank Prof. Nunzia Tannoia for the gift of the -(α)20.5 sample and Dr. Maurizio Travi for the IVS I pentanucleotide deletion sample. This work was partially supported by Fondazione Leonardo Giambrone per la Guarigione dalla Thalassemia and MURST 60 %. A.R. is a Ph. D. student of “Dottorato di Genetica Umana” of the University of Torino.

Received June 6, 1997, accepted August 19, 1997.
Molecular diagnosis of α-thal in microcytosis

71.4-80 fL) and mean Hb was 13.6 (range 12.2-15.2 g/dL) in –α/Hb 3.7 heterozygotes. No statistically significant difference was observed in Hb and MCV values in carriers of the different defects, which was probably due to the limited number of cases (not shown).

Discussion
The finding of microcytic red cells is a common problem in hematological practice. α-thalassemia is usually a presumptive diagnosis, after exclusion of β-thalassemia and iron deficiency. Although anemia is absent or unremarkable, it is important to diagnose α-thalassemia, in order to reassure patients and to avoid repeated and/or expensive analyses. Only the molecular approach allows for the precise diagnosis of α-thalassemia state. In screening five different mutations, we typed 82% of our patients. Other recent studies have used a similar approach to test patients with microcytosis, reporting that a variable proportion of the cases analyzed is related to α-thalassemia. Careful selection of the samples increases the possibility of a correct diagnosis. However, in all series, a small proportion of patients remains undiagnosed. These cases may be explained by other undefined or unscreened forms of α-thalassemia. Family studies and globin chain synthesis may be useful in forms caused by unknown mutations. Some of the α-thalassemia defects reported in Italy and not analyzed in this work are considered rare cases. However, PCR-based tests are available for –α-Cal5 and –α/Hb 5.2. It is likely that the number of undiagnosed cases will progressively decrease in the future as new forms of α-thalassemia are identified and became susceptible to molecular analysis.

Table 1. Frequency of the different α-thalassemia genotypes and alleles in the series examined.

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>heterozygotes N. (%)</th>
<th>homozygotes N. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>–α 3.7</td>
<td>19 45</td>
<td>5 12</td>
</tr>
<tr>
<td>––Med</td>
<td>3 7</td>
<td></td>
</tr>
<tr>
<td>–20.5</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Nco I</td>
<td>5 12</td>
<td>5 12</td>
</tr>
<tr>
<td>Hph I</td>
<td>4 10</td>
<td>1 2</td>
</tr>
<tr>
<td>Total n.</td>
<td>31</td>
<td>11</td>
</tr>
</tbody>
</table>

Allele frequency in the series studied

<table>
<thead>
<tr>
<th>N. %</th>
<th>N. %</th>
<th>N. %</th>
<th>N. %</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>55</td>
<td>3 5.5</td>
<td>15 29</td>
</tr>
</tbody>
</table>

*% refers to the total number of patients.

References